Shire announced results of a Phase 3 study which demonstrated the long-term maintenance of efficacy of lisdexamfetamine dimesylate (LDX) in children and adolescents aged 6–17 years with moderately symptomatic Attention-Deficit/Hyperactivity Disorder (ADHD).
The trial was a double-blind, placebo-controlled, randomized withdrawal, multicenter, extension study to evaluate the long-term maintenance of efficacy, as well as safety, of LDX. Children and adolescents diagnosed with ADHD were treated with LDX (30, 50 or 70mg/day) during an open-label period (comprising dose optimization, maintenance, and fixed dose periods) of at least 26 weeks before entering a 6-week double-blind randomized withdrawal period, where subjects received either LDX or placebo.
Results showed maintenance of efficacy in children and adolescents who continued to receive LDX, as demonstrated by a significantly lower proportion of ADHD treatment failures (13.5%) in this group, compared with placebo (65.8%); and the majority of placebo-treated subjects who met protocol-defined ADHD symptom relapse criteria did so within 2 weeks following randomization. Relapse or treatment failure in this study was determined to have occurred when a subject has both a ≥50% increase (or worsening) in ADHD-Rating Scale-IV (ADHD-RS-IV) total score, and a ≥2-point increase (or worsening) in Clinical Global Impressions-Severity of Illness (CGI-S) rating scale score, at any double-blind visit relative to the respective scores at randomization.
LDX (Vyvanse; Shire) is a schedule II narcotic approved for the treatment of ADHD in children and adolescents aged 6–17 and adults, as well as maintenance treatment of ADHD in adults 18–55 years of age. A stimulant, LDX is a prodrug of dextroamphetamine. After oral administration, LDX is rapidly absorbed from the gastrointestinal tract and hydrolyzed primarily in whole blood to dextroamphetamine, which is responsible for the drug’s activity.
For more information call (800) 536-7878 or visit www.shire.com.